ANDA Case Filings Drop 32%, But Still High Compared To Last Decade
Lex Machina reports that 316 ANDA cases were filed in 2016 compared to 468 in 2015; number of inter partes review petitions filed on Orange Book patents has declined since 2015.
You may also be interested in...
In an unusual twist, district court ruled Acorda patents invalid after company defeated Kyle Bass' inter partes review challenge; Bass has won 10 IPR decisions, lost 9 and has one pending.
Purdue's OxyContin and Amarin's Vascepa lead the list of targets as an increasing number of generic firms take up litigation.
Agency’s apparent ‘intellectual exercise’ in treating pre-Hatch-Waxman ANDAs as NDAs could expose biosimilars to liability, Teva deputy general counsel notes at FDLI conference.